1,3-二氢咪唑并[4,5-b]吡啶-2-酮 | 16328-62-4

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 1,3-二氢咪唑并[4,5-b]吡啶-2-酮
• 中文别名: 1H-咪唑并[4,5-B]吡啶-2(3H)酮；1,3-二氢-2H-咪唑并[4,5-b]吡啶-2-酮
• 英文名称: 1,3-dihydro-imidazo[4,5-b]pyridin-2-one
• 英文别名: 1H-imidazo[4,5-b]pyridin-2(3H)-one；1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one；2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-one；1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one；Imidazo<4,5-b>-Pyridin-2-on；1,3-dihydroimidazo[4,5-b]pyridin-2-one
• CAS: 16328-62-4
• 化学式: C₆H₅N₃O
• mdl: MFCD00464845
• 分子量: 135.125
• InChiKey: PGDIPOWQYRAOSK-UHFFFAOYSA-N

物化性质

• 熔点：
  274 °C
• 密度：
  1.62±0.1 g/cm3(Predicted)
• 保留指数：
  1740;1740

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,3-Dihydro-2h-imidazo[4,5-b]pyridin-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,3-Dihydro-2h-imidazo[4,5-b]pyridin-2-one
CAS number: 16328-62-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5N3O
Molecular weight: 135.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二氢咪唑并[4,5-b]吡啶-2-酮 在 sodium acetate 、 氯 作用下， 以 溶剂黄146 为溶剂， 反应 5.0h， 以79%的产率得到5,6-dichloroimidazo[4,5-b]pyridin-2-one
  参考文献：
  名称：

  Halogenation of Imidazo[4,5-b]pyridin-2-one Derivatives

  摘要：

  在醋酸中，以90–95°C对2,3-二氢-1H-咪唑[4,5-b]吡啶-2-酮及其N-甲基取代衍生物进行氯化和溴化，会形成相应的5,6-二氯（或二溴）-2,3-二氢-1H-咪唑[4,5-b]吡啶-2-酮。在类似条件下，使用ICl对相同底物进行碘化会生成6-碘衍生物。对6-碘-1,3-二甲基-2,3-二氢-1H-咪唑[4,5-b]吡啶-2-酮进行氯化时，碘原子被氯取代，生成5,6-二氯-1,3-二甲基-2,3-二氢-1H-咪唑[4,5-b]吡啶-2-酮。对6-溴和6-氯-2,3-二氢-1H-咪唑[4,5-b]吡啶-2-酮进行溴化分别得到5,6-二溴-和5-溴-6-氯-2,3-二氢-1H-咪唑[4,5-b]吡啶-2-酮。

  DOI：

  10.1007/s11178-005-0206-y
• 作为产物：
  描述：

  2-氨基烟酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.0h， 以77%的产率得到1,3-二氢咪唑并[4,5-b]吡啶-2-酮
  参考文献：
  名称：

  灵长类动物大脑中双5-羟色胺7（5-HT 7）/ 5-羟色胺2A（5-HT 2A）受体拮抗剂的合理设计，药物调节和合成，并通过[ 18 F] -PET成像进行评估

  摘要：

  我们报告了46个含叔胺的N-烷基化苯并[ d ]咪唑-2（3 H）-ones，咪唑并[4,5 - b ]吡啶-2（3 H）-ones，咪唑并[4,5 ]的合成- ç ]吡啶-2（3 H ^） -酮，苯并[ d ]唑-2（3 H ^） -酮，恶唑并[4,5- b ]吡啶-2（3 H ^） -酮和ñ，ñ ' -二烷基化的苯并[ d ]咪唑-2（3 H）-ones。针对5-HT 7 R，5-HT 2A R，5-HT 1A R和5-HT 6评估了这些化合物R为有效的双重5-HT 7 / 5-HT 2A血清素受体配体。对芳香环及其取代基，烷基链长和叔胺的结构-活性关系进行了彻底的研究。1-（4-（4-（4-氟苯甲酰基）哌啶-1-基）丁基）-1 H-苯并[ d ]咪唑-2（3 H）-一（79）和1-（6-（4- （4-氟苯甲酰基）哌啶-1-基己基）-1 H-苯并[ d ]咪唑-2（3 H）-一（81）

  DOI：

  10.1021/acs.jmedchem.5b00874

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2021004547A1

  公开（公告）日：2021-01-14

  This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)

  这项披露涉及杂环化合物作为HPK1的抑制剂，特别涉及公式I的化合物或其药用盐，以及包含该化合物的药物组合物，用于治疗HPK1介导的疾病和状况，如癌症。 (I)
• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• [EN] RESPIRATORY SYNCYTIAL VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：MEDIVIR AB

  公开号：WO2015065336A1

  公开（公告）日：2015-05-07

  Compounds of Formula (I): wherein R1, R2 and R3 are defined herein, are useful as inhibitors of RSV.

  式(I)的化合物：其中R1、R2和R3如本文所定义，可用作RSV的抑制剂。
• [EN] N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES CONTENANT N EN TANT QU'INHIBITEURS DE KINASE JAK3
  申请人：PALAU PHARMA SA

  公开号：WO2011051452A1

  公开（公告）日：2011-05-05

  N-containing heteroaryl derivatives of formula I or II, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK, particularly JAK3, kinase inhibitors.

  式I或II的含氮杂环衍生物，其中各取代基的含义如描述中所披露的。这些化合物可用作JAK，特别是JAK3激酶抑制剂。
• A straightforward synthesis of pentosidine framework
  作者：Yahua Liu、Weihan Zhang、Lawrence M. Sayre

  DOI：10.1002/jhet.374

  日期：——

  Pentosidine framework 4-butyl-2-propyl-4H-aminoimidazo[4,5-b]pyridine () was synthesized through a five steps reaction sequence. The regiochemistry of was confirmed by an unambiguous synthesis, and the UV absorption and fluorescent properties of were examined. J. Heterocyclic Chem., (2010).

  戊糖骨架4-丁基-2-丙基-4 H-氨基咪唑并[4,5- b ]吡啶（通过五步反应序列合成）。的区域化学 通过明确的合成得到了证实，并且该化合物的紫外线吸收和荧光性质 被检查了。J.杂环化​​学。（2010）。

表征谱图